Harvard Bioscience Q3 2026 slides: revenue rises 8%, margins compress

Harvard Bioscience reported Q3 2026 revenue growth of 8%, driven by CRO demand and new product innovations. China revenue rose 31% year-over-year. Gross margins were pressured by lower-margin products. Full-year revenue guidance was reaffirmed at 3-5% growth, but adjusted EBITDA guidance was lowered. Project Viking is expected to deliver cost savings in 2027. Management expects to launch a bioproduction version of electroporation technology in mid-2027.

Harvard Bioscience (HBIO) reported Q3 2026 revenue of $22.2M, up 8% YoY, driven by CRO and distribution partner demand. Adjusted EBITDA was $1.8M, impacted by lower-margin products. The company reaffirmed full-year revenue guidance of 3-5% growth and adjusted gross margin target of 57-59%. Project Viking, a manufacturing consolidation plan, is on track for 2027 completion, expected to generate $3M in cost savings.

HARVARD BIOSCIENCE INC (HBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Harvard Bioscience Announces Third Quarter 2026 Financial Results · Third Quarter 2026 Revenue Growth of 8% Year Over Year to $22.2 Million · Reaffirms Full Year 2026 Revenue Guidance of 3%-5% Year Over Year Growth HOLLISTON, Mass., November 10, 2026 (GLOBE NEWSWIRE)

Harvard Bioscience (HBIO) reported Q2 2026 revenue of $22.7M, up 11%, and adjusted EBITDA of $1.7M, up 11%. Full-year revenue guidance was raised to 3-5% growth, but gross margin guidance was lowered to 57-59% due to product and geographic mix shifts. The company expects $3M in cost savings from Project Viking in 2027. Americas and APAC regions showed strong growth, while Europe grew modestly. Adjusted EPS was -$0.14, and Q3 revenue guidance is $21.0M-$22.6M.

Harvard Bioscience (HBIO) reported Q2 2026 revenue up 11%, driven by CRO demand and double-digit growth in telemetry and CMT portfolios. China sales rose on its “Made in China” BTX line. Recurring revenue reached 55%. Full-year guidance raised to 3% to 5% growth, but adjusted gross margin cut 100 bps to 57% to 59%, with Project Viking cost savings.

Benchmark raised its price target for Harvard Bioscience (NASDAQ:HBIO) to $7.50 from $6.00 and kept a Speculative Buy rating after Q2 results. Q2 revenue was $22.7M, above guidance and consensus. Full-year 2026 revenue growth guidance was lifted to 3% to 5%. Adjusted gross margin target was lowered to 57% to 59%.